000148283 001__ 148283
000148283 005__ 20240229123030.0
000148283 0247_ $$2doi$$a10.1002/ijc.32814
000148283 0247_ $$2pmid$$apmid:31782150
000148283 0247_ $$2ISSN$$a0020-7136
000148283 0247_ $$2ISSN$$a1097-0215
000148283 037__ $$aDKFZ-2019-02849
000148283 041__ $$aeng
000148283 082__ $$a610
000148283 1001_ $$00000-0002-8014-2652$$aHeidler, Christopher L$$b0
000148283 245__ $$aPrexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib.
000148283 260__ $$aBognor Regis$$bWiley-Liss$$c2020
000148283 3367_ $$2DRIVER$$aarticle
000148283 3367_ $$2DataCite$$aOutput Types/Journal article
000148283 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1597220246_8519
000148283 3367_ $$2BibTeX$$aARTICLE
000148283 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000148283 3367_ $$00$$2EndNote$$aJournal Article
000148283 500__ $$a2020 Aug 15;147(4):1059-1070
000148283 520__ $$aProgress in the systemic control of osteosarcoma has been limited over the past decades thus indicating the urgent clinical need for the development of novel treatment strategies. Therefore, we have recently developed new preclinical models to study promising novel agents for the treatment of pediatric osteosarcoma. The checkpoint kinase (chk) inhibitor prexasertib (LY2606368) and its salt form (LSN2940930) have recently been shown to be active in adult and pediatric malignancies, including sarcoma. We have now tested the potency of prexasertib in clonogenic survival assays in two new lines of primary patient-derived osteosarcoma cells and in two established osteosarcoma cell lines as a single agent and in combination with cisplatin and the poly ADP-ribose polymerase (PARP) inhibitor talazoparib. Prexasertib alone results in strongly reduced clonogenic survival at low nanomolar concentrations and acts by affecting cell cycle progression, induction of apoptosis and induction of double-stranded DNA breakage at concentrations that are well below clinically tolerable and safe plasma concentrations. In combination with cisplatin and talazoparib, prexasertib acts in a synergistic fashion. Chk1 inhibition by prexasertib and its combination with the DNA damaging agent cisplatin and the PARP-inhibitor talazoparib thus emerges as a potential new treatment option for pediatric osteosarcoma which will now have to be tested in preclinical primary patient derived in vivo models and clinical studies. This article is protected by copyright. All rights reserved.
000148283 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000148283 588__ $$aDataset connected to CrossRef, PubMed,
000148283 7001_ $$aRoth, Eva K$$b1
000148283 7001_ $$aThiemann, Markus$$b2
000148283 7001_ $$0P:(DE-HGF)0$$aBlattmann, Claudia$$b3
000148283 7001_ $$0P:(DE-He78)c5a1a98649a7874de0def093eb136262$$aLopez Perez, Ramon$$b4$$udkfz
000148283 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter E$$b5$$udkfz
000148283 7001_ $$aKovac, Michal$$b6
000148283 7001_ $$aAmthor, Beate$$b7
000148283 7001_ $$aNeu-Yilik, Gabriele$$b8
000148283 7001_ $$aKulozik, Andreas E$$b9
000148283 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.32814$$gp. ijc.32814$$n4$$p1059-1070$$tInternational journal of cancer$$v147$$x1097-0215$$y2020
000148283 909CO $$ooai:inrepo02.dkfz.de:148283$$pVDB
000148283 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000148283 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c5a1a98649a7874de0def093eb136262$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000148283 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000148283 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000148283 9141_ $$y2020
000148283 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000148283 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000148283 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000148283 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000148283 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000148283 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000148283 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000148283 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000148283 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000148283 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000148283 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000148283 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000148283 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Translationale Radioonkologie$$x0
000148283 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000148283 980__ $$ajournal
000148283 980__ $$aVDB
000148283 980__ $$aI:(DE-He78)E055-20160331
000148283 980__ $$aI:(DE-He78)HD01-20160331
000148283 980__ $$aUNRESTRICTED